RD-133

N/A

Report date: 2023/12/06 20:07:23

Base Information

Drug NameRD-133
Drug Alias NameRD133
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Mesothelin
TargetsMesothelin
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Iaso Biotherapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Iaso Biotechnology Co LtdNanjing Iaso Biotherapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A